



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 8067

Title: Human Liver stem/progenitor cells decrease serum bilirubin in hyperbilirubinemic Gunn rat

Reviewer code: 02441335

Science editor: Ma, Ya-Juan

Date sent for review: 2013-12-16 08:38

Date reviewed: 2014-01-03 10:52

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This study shows an interesting result that ADHLSC (adult stem/progenitor cells from adult human liver) engraftment into Gunn rat's liver can significantly reduce the serum bilirubin levels, suggesting that ADHLSC might be a promising candidate for treatment of Crigler-Najjar type I syndrome. 1. I hope the authors may further state that as an adult stem/progenitor cells, whether ADHLSC may show stem cell markers? And why these cells do not express biliary markers and do not differentiate into biliary cell? 2. What is the outcome of ADHLSC after 60 days post-transplantation into Gunn rats (UGT1A1 deficient animal)? 3. I hope the authors may further discuss the limitation or potential risk of ADHLSC-based cell therapy, and your strategy.